Results 221 to 230 of about 8,339,405 (403)
Letter to the editor. Gene editing and disabled people : a response to Iñigo de Miguel Beriain [PDF]
Boardman, Felicity K.
core +1 more source
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek +2 more
wiley +1 more source
Gene editing to enhance biotic stress tolerance in sugarcane. [PDF]
Altpeter F.
europepmc +1 more source
IqgC is a RasGAP from Dictyostelium discoideum. IqgC binds RasG via its RasGAP domain and deactivates it on macroendocytic cups, thereby suppressing the uptake of fluid and particles. IqgC has a positive effect on cell‐substratum adhesion, and its RGCt domain is required for recruitment to ventral foci.
Vedrana Filić +3 more
wiley +1 more source
CRISPR and gene editing technologies for bleeding disorders. [PDF]
VandenDriessche T, Janssens M, Chuah MK.
europepmc +1 more source
Generating Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) gene deletions in Bladder Cancer Cell Lines [PDF]
Adam Dooner
openalex
Interplay between RNA‐protein interactions and RNA structures in gene regulation
Methodological advances in mapping transcriptome‐wide RNA‐protein interactions and RNA structures have started to uncover the potential of RNP conformations in gene regulation. Competing RNA–RNA, RNA‐protein and protein–protein interactions shape the compaction and function of RNPs throughout their lifetime and may provide novel therapeutic targets in ...
Jenni Rapakko +2 more
wiley +1 more source
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee +3 more
wiley +1 more source

